Loading...

Andrew Ko, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone415-353-7286
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Brown University, Providence, RISc.B.05/1991Applied Mathematics and Biology
    Johns Hopkins School of Medicine, Baltimore, MDM.D.05/1995Medicine
    Beth Israel/Harvard Medical School, Boston, MA06/1998Internal Medicine (internship and residency)
    Stanford University, Palo Alto, CA06/2001Medical oncology (fellowship)
    University of California, San Francisco, CA2018Diversity, Equity, and Inclusion Champion Training

    Collapse Research 
    Collapse Research Activities and Funding
    Dual Targeting of MEK and EGFR Signaling Pathways in Advanced Pancreatic Cancer
    NIH/NCI R21CA149939Sep 19, 2011 - Aug 31, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse Student Projects
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Mol Ther. 2020 Jul 21. Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL. PMID: 32730744.
      View in: PubMed   Mentions:    Fields:    
    2. Multicenter phase II study of Cabazitaxel in advanced gastroesophageal cancer: Association of HER2 Expression and M2-like Tumor Associated Macrophages with Patient Outcome. Clin Cancer Res. 2020 Jul 08. Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PA, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ, Zhang C, Kaur N, Elmonshed D, Galletti G, Sarkar S, Bhinder B, Pittman ME, Plotnikova OM, Kotlov N, Frenkel FE, Bagaev AV, Elemento O, Betel D, Giannakakou P, Lenz HJ. PMID: 32641434.
      View in: PubMed   Mentions:    Fields:    
    3. Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature. Anticancer Res. 2020 Jul; 40(7):3995-4000. Burns ST, Damon L, Akagi N, Laszik Z, Ko AH. PMID: 32620643.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. A Phase 2 Study of Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer. Clin Cancer Res. 2020 Jun 26. Wu AA, Bever KM, Ho WJ, Fertig EJ, Niu N, Zheng L, Parkinson RM, Durham JN, Onners BL, Ferguson A, Wilt C, Ko AH, Wang-Gillam A, Laheru DA, Anders RA, Thompson ED, Sugar EA, Jaffee EM, Le DT. PMID: 32591464.
      View in: PubMed   Mentions:    Fields:    
    5. Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)': Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79-87. Ann Oncol. 2020 Jun 04. Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algül H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH. PMID: 32507672.
      View in: PubMed   Mentions:    Fields:    
    6. Factors Impacting Differential Outcomes in the Definitive Radiation Treatment of Anal Cancer Between HIV-Positive and HIV-Negative Patients. Oncologist. 2020 May 10. Susko M, Wang CJ, Lazar AA, Kim S, Laffan A, Feng M, Ko A, Venook AP, Atreya CE, Van Loon K, Anwar M. PMID: 32390297.
      View in: PubMed   Mentions:    Fields:    
    7. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Clin Cancer Res. 2020 Apr 09. Tsujikawa T, Crocenzi T, Durham JN, Sugar EA, Wu AA, Onners B, Nauroth JM, Anders RA, Fertig EJ, Laheru DA, Reiss K, Vonderheide RH, Ko AH, Tempero MA, Fisher GA, Considine M, Danilova L, Brockstedt DG, Coussens LM, Jaffee EM, Le DT. PMID: 32273276.
      View in: PubMed   Mentions: 1     Fields:    
    8. Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer. Oncologist. 2020 Feb 07. Ursem C, Zhou M, Paciorek A, Atreya CE, Ko AH, Venook A, Zhang L, Van Loon K. PMID: 32031306.
      View in: PubMed   Mentions:    Fields:    
    9. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE). Ann Oncol. 2020 01; 31(1):79-87. Kundranda M, Gracian AC, Zafar SF, Meiri E, Bendell J, Algül H, Rivera F, Ahn ER, Watkins D, Pelzer U, Charu V, Zalutskaya A, Kuesters G, Pipas JM, Santillana S, Askoxylakis V, Ko AH. PMID: 31912800.
      View in: PubMed   Mentions: 2     Fields:    
    10. CA 19-9 Response: A Surrogate to Predict Survival in Patients With Metastatic Pancreatic Adenocarcinoma. Am J Clin Oncol. 2019 12; 42(12):898-902. Diaz CL, Cinar P, Hwang J, Ko AH, Tempero MA. PMID: 31634155.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation. J Gastrointest Cancer. 2019 Dec; 50(4):769-779. Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K. PMID: 30058032.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    12. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst. 2019 08 01; 111(8):782-794. Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. PMID: 31086963.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    13. Adjuvant Therapy for Ampullary Cancer. JAMA Surg. 2019 Aug 01; 154(8):715. Ko AH, Nakakura EK. PMID: 31141140.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma. Pancreas. 2019 08; 48(7):927-930. Johns C, Diaz CL, Hwang J, Kerridge WD, Ko AH, Tempero MA. PMID: 31268983.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study). Clin Cancer Res. 2019 Sep 15; 25(18):5493-5502. Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein P, Morse MA, Zeh HJ, Weekes C, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru D, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM. PMID: 31126960.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    16. Effects of surgical targeting in laser interstitial thermal therapy for mesial temporal lobe epilepsy: A multicenter study of 234 patients. Epilepsia. 2019 06; 60(6):1171-1183. Wu C, Jermakowicz WJ, Chakravorti S, Cajigas I, Sharan AD, Jagid JR, Matias CM, Sperling MR, Buckley R, Ko A, Ojemann JG, Miller JW, Youngerman B, Sheth SA, McKhann GM, Laxton AW, Couture DE, Popli GS, Smith A, Mehta AD, Ho AL, Halpern CH, Englot DJ, Neimat JS, Konrad PE, Neal E, Vale FL, Holloway KL, Air EL, Schwalb J, Dawant BM, D'Haese PF. PMID: 31112302.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    17. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. 2019 04; 18(2):241-251. Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. PMID: 30267352.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Pancreatic Adenocarcinoma, Version 1.2019. J Natl Compr Canc Netw. 2019 03 01; 17(3):202-210. Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. PMID: 30865919.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    19. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization? Am J Surg Pathol. 2019 03; 43(3):334-340. Kim SS, Ko AH, Nakakura EK, Wang ZJ, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Kim GE. PMID: 30211728.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Understanding Pancreatic Diseases Using Animated Pancreas Patient: Informing Patients for Better Health Outcomes With Visual Formats of Learning. Pancreas. 2018 Nov/Dec; 47(10):1256-1261. Munigala S, Gardner TB, O'Reilly EM, Castillo CF, Ko AH, Pleskow D, Mills JB, Vollmer CM, Searle NA, Alsante M, Holt JM, Gelrud A. PMID: 30286013.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Moving from late to early stage disease: lessons learned from erlotinib in pancreatic cancer. Hepatobiliary Surg Nutr. 2018 Oct; 7(5):406-408. Ko AH. PMID: 30498720.
      View in: PubMed   Mentions:
    22. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 11; 211(5):1010-1019. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. PMID: 30063366.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 05 10; 4(5):e180013. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. PMID: 29543932.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCTClinical Trials
    24. Shifting the treatment model for resectable pancreatic cancer. Lancet Gastroenterol Hepatol. 2018 06; 3(6):375-376. Ko AH. PMID: 29625842.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044. Heymach J, Krilov L, Alberg A, Baxter N, Chang SM, Corcoran RB, Dale W, DeMichele A, Magid Diefenbach CS, Dreicer R, Epstein AS, Gillison ML, Graham DL, Jones J, Ko AH, Lopez AM, Maki RG, Rodriguez-Galindo C, Schilsky RL, Sznol M, Westin SN, Burstein H. PMID: 29380678.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    26. Clinical Management: Metastatic Disease. Cancer J. 2017 Nov/Dec; 23(6):355-361. Ko AH. PMID: 29189332.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial. Oncologist. 2017 12; 22(12):1427-e129. Ko AH, Murphy PB, Peyton JD, Shipley DL, Al-Hazzouri A, Rodriguez FA, Womack MS, Xiong HQ, Waterhouse DM, Tempero MA, Guo S, Lane CM, Earwood C, DeBusk LM, Bendell JC. PMID: 28935773.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    28. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 08; 15(8):1028-1061. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. PMID: 28784865.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    29. Gastrocutaneous Fistula in a Patient with Locally Recurrent MSI-High Colorectal Cancer: Local Complications Arising from Therapeutic Response to Immune Checkpoint Blockade. Anticancer Res. 2017 07; 37(7):3679-3684. Greene C, Nakakura EK, Ko AH. PMID: 28668860.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. Oncologist. 2017 09; 22(9):1024-e89. Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J. PMID: 28592615.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    31. Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017. Chin Clin Oncol. 2017 Jun; 6(3):29. Cinar P, Ko AH. PMID: 28705006.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    32. A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature. J Gastrointest Cancer. 2017 Mar; 48(1):94-99. Kim SS, Kim GE, Ko AH. PMID: 26961789.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab. Am J Clin Oncol. 2016 12; 39(6):614-618. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. PMID: 25068471.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    34. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. PMID: 28078110.
      View in: PubMed   Mentions:
    35. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 11; 45(10):1394-1400. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. PMID: 27171514.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    36. Striving to Move Beyond Chemotherapy in Advanced Pancreatic Cancer. J Oncol Pract. 2016 09; 12(9):808-10. Ko AH. PMID: 27621334.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity. J Surg Oncol. 2016 Dec; 114(7):838-847. Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. PMID: 27569043.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    38. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016 Oct; 114(5):587-596. Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. PMID: 27444658.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    39. Safety and clinical response of intraventricular caspofungin for Scedosporium apiospermum complex central nervous system infection. Med Mycol Case Rep. 2016 Sep; 13:1-4. Williams JR, Tenforde MW, Chan JD, Ko A, Graham SM. PMID: 27656356.
      View in: PubMed   Mentions:
    40. New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. Clin Cancer Res. 2016 Sep 01; 22(17):4283-90. Wang VE, Grandis JR, Ko AH. PMID: 27370606.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    41. Raising the bar for the adjuvant treatment of pancreatic cancer. Lancet. 2016 Jul 16; 388(10041):214-5. Ko AH. PMID: 27265348.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    42. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 08 01; 34(22):2654-68. Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS. PMID: 27247216.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    43. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. Int J Nanomedicine. 2016; 11:1225-35. Ko AH. PMID: 27099488.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    44. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs. 2016 06; 34(3):319-28. Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B. PMID: 26994014.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    45. Pancreatic Cancer and the Possibility of Long-term Survival: A Glimmer of Hope? JAMA Oncol. 2016 Mar; 2(3):380-1. Ko AH. PMID: 26658827.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar; 45(3):370-5. Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. PMID: 26390428.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    47. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. PMID: 26875185.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    48. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016 Apr; 27(4):654-60. Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. PMID: 26802160.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    49. MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Future Oncol. 2016 Feb; 12(4):453-64. Carnevale J, Ko AH. PMID: 26685802.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    50. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 01; 22(1):61-8. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasaz A, Kuhn P, Tempero MA, Collisson EA, Kelley RK, Venook AP, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. PMID: 26251290.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCellsCTClinical Trials
    51. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. PMID: 26109333.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    52. Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am. 2015 Aug; 29(4):741-59. Pollom EL, Koong AC, Ko AH. PMID: 26226908.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    53. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol. 2015 Jun 01; 33(16):1779-86. Ko AH. PMID: 25918299.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    54. Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study. Cancer. 2015 Apr 15; 121(8):1287-94. Walker EJ, Ko AH, Holly EA, Bracci PM. PMID: 25649483.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    55. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Am Soc Clin Oncol Educ Book. 2015; e222-7. Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS. PMID: 25993177.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    56. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol. 2014 Dec; 5(6):E88-95. Walker EJ, Simko JP, Nakakura EK, Ko AH. PMID: 25436138.
      View in: PubMed   Mentions:
    57. Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. Int J Cancer. 2015 Mar 15; 136(6):E646-53. Walker EJ, Ko AH, Holly EA, Bracci PM. PMID: 25091126.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    58. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. PMID: 25099441.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    59. Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor. Anticancer Res. 2014 Jul; 34(7):3629-34. Walker EJ, Simko JP, Ko AH. PMID: 24982379.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    60. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. PMID: 24448917.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    61. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. PMID: 24622062.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    62. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014 Jun 15; 120(12):1780-6. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. PMID: 24633933.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    63. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol. 2014 Mar 07; 20(9):2224-36. Walker EJ, Ko AH. PMID: 24605022.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    64. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2014 Feb; 12(2):167-72. Cinar P, Ko AH. PMID: 24586078.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    65. Expanding options for pancreatic cancer... so where do we go from here? Oncology (Williston Park). 2014 Jan; 28(1):5. Ko AH. PMID: 24683713.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    66. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 01; 109(7):1725-34. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. PMID: 24022191.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    67. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther. 2013 Oct; 12(10):2213-25. Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. PMID: 23918833.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    68. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20; 109(4):920-5. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. PMID: 23880820.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    69. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. PMID: 23519998.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    70. Stabilization of p21 (Cip1/WAF1) following Tip60-dependent acetylation is required for p21-mediated DNA damage response. Cell Death Differ. 2013 Apr; 20(4):620-9. Lee MS, Seo J, Choi DY, Lee EW, Ko A, Ha NC, Yoon JB, Lee HW, Kim KP, Song J. PMID: 23238566.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    71. Two patients with primary sellar leiomyomas, a rare entity. J Clin Neurosci. 2013 Jun; 20(6):897-901. Ko A, Su DK, Born D, DeSantis A, Alan Failor R, Ferreira M. PMID: 23219820.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    72. Achieving the best of both worlds. J Clin Oncol. 2013 Jan 01; 31(1):3-4. Ko AH, Cella D. PMID: 23213099.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    73. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. PMID: 21552099.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    74. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012 Dec; 70(6):875-81. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. PMID: 23053263.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    75. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 01; 10(6):703-13. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. PMID: 22679115.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    76. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012 Feb; 9(1):016003. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. PMID: 22306768.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCells
    77. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012 Feb; 9(1):016001. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. PMID: 22306705.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCells
    78. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012 Jan 01; 30(1):88-109. Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG. PMID: 22147736.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansPHPublic Health
    79. FOLFIRINOX: a small step or a great leap forward? J Clin Oncol. 2011 Oct 01; 29(28):3727-9. Ko AH. PMID: 21900100.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    80. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1597-606. Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. PMID: 21629990.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    81. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr; 17(4):500-3. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. PMID: 21460848.
      View in: PubMed   Mentions: 309     Fields:    Translation:HumansAnimalsCells
    82. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage. 2011 May; 19(5):515-42. Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, Gardiner J, Garnero P, Hardin J, Henrotin Y, Heinegård D, Ko A, Lohmander LS, Matthews G, Menetski J, Moskowitz R, Persiani S, Poole AR, Rousseau JC, Todman M. PMID: 21396468.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    83. "And what other medications are you taking?". J Clin Oncol. 2011 Apr 10; 29(11):e288-91. Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. PMID: 21245436.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    84. Radiation therapy in operable and locally advanced pancreatic cancer. J Natl Compr Canc Netw. 2010 Sep; 8(9):1022-31. Ko AH, Crane CH. PMID: 20876542.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    85. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. PMID: 20130876.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    86. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. PMID: 19706807.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    87. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5. Ko AH, Tempero MA. PMID: 19041649.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    88. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. PMID: 18815548.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    89. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. PMID: 18379729.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    90. Erlotinib in the treatment of advanced pancreatic cancer. Biologics. 2008 Mar; 2(1):83-95. Kelley RK, Ko AH. PMID: 19707431.
      View in: PubMed   Mentions:
    91. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. PMID: 18181045.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    92. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother. 2007 Oct; 30(7):762-72. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. PMID: 17893568.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsCTClinical Trials
    93. Future strategies for targeted therapies and tailored patient management in pancreatic cancer. Semin Oncol. 2007 Aug; 34(4):354-64. Ko AH. PMID: 17674964.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    94. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage. 2007 Dec; 15(12):1348-56. Puopolo A, Boice JA, Fidelholtz JL, Littlejohn TW, Miranda P, Berrocal A, Ko A, Cichanowitz N, Reicin AS. PMID: 17631392.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    95. Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California. Cancer Causes Control. 2007 Oct; 18(8):809-19. Ko AH, Wang F, Holly EA. PMID: 17632765.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    96. Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson's disease. Mov Disord. 2007 Apr 15; 22(5):640-4. Lam K, Lam FK, Lau KK, Chan YK, Kan EY, Woo J, Wong FK, Ko A. PMID: 17266075.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    97. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 01; 68(3):809-16. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. PMID: 17363191.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    98. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. PMID: 16344320.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    99. Systemic therapy for pancreatic cancer. Semin Radiat Oncol. 2005 Oct; 15(4):245-53. Ko AH, Tempero MA. PMID: 16183478.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    100. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw. 2005 Sep; 3(5):627-36. Ko AH, Tempero MA. PMID: 16194454.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    101. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. PMID: 15999098.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    102. Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature. Dig Dis Sci. 2003 Jan; 48(1):192-6. Ko AH, Bergsland EK, Lee GA. PMID: 12645810.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    103. Clinical outcomes associated with very late relapses in diffuse large cell lymphoma. Leuk Lymphoma. 2002 Sep; 43(9):1789-93. Ko AH, Yuen AR. PMID: 12685833.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    104. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep. 2002 May; 4(3):202-12. Ko AH, Tempero MA. PMID: 11937010.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    105. Hedgehog signaling in gastrointestinal development and disease. Curr Mol Med. 2002 Feb; 2(1):67-82. Harmon EB, Ko AH, Kim SK. PMID: 11898849.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    106. AR and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol. 2002 Jan; 16(1):85-99. Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, Balk SP. PMID: 11773441.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    107. Radiation after mastectomy in high-risk patients: is it necessary? Am Surg. 2001 Dec; 67(12):1209-12. Patterson S, Ko A, O'Connell TX. PMID: 11768832.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    108. Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells. Br J Cancer. 1998; 77(2):181-5. Chen Z, Ko A, Yang J, Jordan VC. PMID: 9460986.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    109. Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996 Apr; 22(4):671-82. Gallant JE, Ko AH. PMID: 8729207.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    110. Non-Hodgkin's lymphoma and Kaposi's sarcoma causing cavitary lung lesions in a patient with AIDS: an HIV-associated collision tumor. AIDS. 1995 Oct; 9(10):1195-7. Ko AH, Thomas DL, Gallant JE. PMID: 8519459.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    111. Repression, denial, backlash: sexually transmitted diseases in the People's Republic of China. Pharos Alpha Omega Alpha Honor Med Soc. 1994; 57(2):11-5. Ko AH. PMID: 8022868.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Andrew's Networks
    Concepts (415)
    Derived automatically from this person's publications.
    _
    Co-Authors (70)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _